The prognosis of vaginal cancer is related to its pathological type, patient’s age and patient’s own physical status. Overall speaking, early stage vaginal cancer without lymph node and distant metastasis has a better prognosis.
Research shows that the overall 5-year survival rate of vaginal cancer is 35%~78%, among which the prognosis of vaginal cancer stage I and II is better. Patients with the pathologic type of adenocarcinoma have a higher 5-year survival rate of 80% to 87%; the 5-year survival rate of staphylosarcoma is roughly 68.4%; and the 5-year survival rate of vaginal melanoma is around 15%, with the worst prognosis.
The treatment of vaginal cancer is based on the patient’s age, stage of the disease, location of the lesion, histopathological type, and size of the tumor, and is treated with radiotherapy, or surgery. Early stage vaginal cancer can be treated by surgery, which can choose transabdominal, transvaginal, or transperitoneal laparoscopic ways to remove vaginal and uterine tissues.